洛铂和草酸铂分别联合替加氟及卡培他滨治疗晚期大肠癌的比较研究

Comparative study of lobaplatin or oxaliplatin combined with tegafur or Xeloda in the treatment of advanced colon cancer

为了探讨草酸铂联合替加氟注射液治疗晚期大肠癌的疗效,对120例晚期大肠癌患者分别接受方案A(31例)、B(33例)、C(34例)和D(22例)治疗。方案A:替加氟(方克)800mg/m2,CIV(24h),d1～d5;LV200mg/m2,静脉滴入(2h),d1～d5,草酸铂(L-OHP)120mg/m2,静脉滴入,d1。方案B:替加氟800mg/m2,CIV(24h),d1～d5,LV200mg/m2,静脉滴入(2h),d1～d5;LBP35mg/m2,静脉滴入,d1。方案C:卡培他滨2500mg/m2,口服,d1～d14;L-OHP135mg/m2,静脉滴入(2h),d1。方案D:卡培他滨(Xeloda)2500mg/m2,口服,d1～d14;LBP35mg/m2,静脉滴入,d1。28d为1个周期。方案A为CR5例,PR14例,有效率61.3%;方案B为CR2例,PR16例,有效率54.5%;方案C为CR5例,PR13例,有效率为52.9%;方案D为CR2例,PR10例,有效率54.5%;方案A优于其他方案,差异无统计学意义,χ2=5.9696,P=0.748。初步研究结果提示,洛铂、草酸铂联合替加氟注射液、卡陪他滨是治疗晚期大肠癌安全有效的治疗方案之一。

The objective of this study was to explore the effect of lobaplatin or oxaliplatin combined with tegafur or Xeloda on the treatment of adbanced colon cancer.One hundred and twenty cases advanced colon cancer were treated with reginmen A（31 cases）,regimen B（33 cases）,regimen C（34 cases）or regimen D（22 cases）.Regimen A：tegafur 800 mg/m^2 CIV（24 h）,d1-d5;LV 200 mg/m^2,ivgtt（2 h）,d1-d5;L-OHP 135 mg/m^2,ivgtt（2 h）,d1.RegimenB：tegafur 800 mg/m^2,CIV（24 h）,d1-d5;LV 200 mg/m^2,ivgtt（2 h）,d1-d5;LBP 35 mg/m^2,ivgtt,d1.Regimen C：Xeloda 2 500 mg/m^2,PO,d1-d14;L-OHP 135 mg/m^2,ivgtt（2 h）,d1.Regimen D：Xeloda 2 500 mg/m^2,PO,d1-d14;L-OHP 135 mg/m^2,ivgtt（2 h）,d1.Regimen A,B,C and D were repeated every 28 days.There were 5 CR,14 PR cases in the regimen A;2 CR,16 PR cases in the regimen B;5 CR,13 PR in the regimen C;2 CR,10 PR cases in the regimen D.The RRs of regimen A,B,C and D were 61.3%,54.5%,52.9% and 54.5% respectively.The difference was statistically significant（χ^2=5.969 6,P=0.748）.Lobaplatin or oxaliplatin combined with tegafur or Xeloda in the treatment of advanced colon cancer is safe and errective.